7.48
+0.11(+1.49%)
Currency In USD
Address
321 Arsenal Street
Cambridge, MA 02472-5710
United States of America
Phone
339 217 0161
Sector
Healthcare
Industry
Biotechnology
Employees
157
First IPO Date
July 24, 2020
| Name | Title | Pay | Year Born |
| Dr. Michel Detheux Ph.D. | President, Chief Executive Officer & Director | 1.04M | 1967 |
| Mr. Matthew Gall | Chief Financial Officer | 648,001 | 1977 |
| Mr. Matthew A. Call M.B.A. | Chief Operating Officer | 706,214 | 1973 |
| Dr. David Feltquate M.D., Ph.D. | Chief Medical Officer | 0 | N/A |
| Mr. Philippe Brantegem | Executive Vice President of Human Resources | 0 | N/A |
| Ms. Adi Osovsky | Executive Vice President of Legal | 0 | N/A |
| Dr. Yvonne McGrath Ph.D. | Chief Scientific Officer | 0 | 1974 |
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.